M&A Deal Summary

Hologic Acquires Diagenode S.A.

On March 1, 2021, Hologic acquired life science company Diagenode S.A. for 159M USD

Acquisition Highlights
  • This is Hologic’s 3rd transaction in the Life Science sector.
  • This is Hologic’s 12th largest (disclosed) transaction.
  • This is Hologic’s 16th transaction in the United States.
  • This is Hologic’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2021-03-01
Target Diagenode S.A.
Sector Life Science
Buyer(s) Hologic
Deal Type Add-on Acquisition
Deal Value 159M USD

Target

Diagenode S.A.

Denville, New Jersey, United States
Diagenode S.A. is a developer and manufacturer of molecular diagnostic assays and epigenetics products. Diagenode offers more than 30 real-time PCR (polymerase chain reaction) tests that are CE-marked for the detection of bacteria, parasites and viruses involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis. Diagenode was founded in 2003 and is based in Denville, New Jersey.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hologic

Marlborough, Massachusetts, United States
Category Company
Founded 1985
Sector Medical Products
Employees6,944
Revenue 4.0B USD (2023)
DESCRIPTION
Hologic's corporate headquarters in Marlborough, Massachusetts.
Hologic's corporate headquarters in Marlborough, Massachusetts.

Hologic is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women throughout the world. Hologic was formed in 1985 and is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 21 of 25
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 20 of 23
State (New Jersey) 1 of 1
Country (United States) 16 of 18
Year (2021) 3 of 5
Size (of disclosed) 12 of 24
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-05 Biotheranostics

San Diego, California, United States

Biotheranostics, Inc. is a commercial-stage molecular diagnostics company that develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. Biotheranostics is based in San Diego, California.

Buy $230M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-08 Mobidiag

Espoo, Finland

Mobidiag is a biotech company specializing in rapid diagnostics of infectious diseases. The company develops and sells fast and accurate molecular diagnostic assays for the diagnosis of pathogenic microbes causing severe infections. Mobidiag was founded in 2000 and is based in Espoo, Finland.

Buy $795M
Mergr

Product

Company

Legal